ClinicalTrials.gg
RecruitingNCT07429955HIP-REGENUpdated Sep 10, 2026

Impact of Pre-operative Sarcopenia on Functional Recovery After Hip Arthroplasty in Older Adults

An interventional study of Total hip replacement and Blood sampling in Sarcopenia in Elderly, Osteoarthritis (OA) and Hip Fracture Surgeries, sponsored by University Hospital, Montpellier. Recruiting at 1 site in France. Open to participants aged 75 Years and older. Per ClinicalTrials.gov, last updated 2026-09-10.

Sponsored by University Hospital, Montpellier · Not applicable, Interventional, and Screening

How we know

From the registry’s dates

  • Started Aug 2026; still recruiting 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
75 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 136 studies in Osteoarthritis with a site in France — 25 open to participants now, 38 under way, 2 of them phase 3. Osteoarthritis · France.

Planned enrollment
74th of 86
20 · median 90
Started
2026
with 8 others
No phase
48 of 136
12 open now
Primary completion
2028-02
later than 20 of 37 live
Registered
128th of 136
by date
Lead sponsor
9 of 136
University Hospital, Montpellier

Among the 136 studies in Osteoarthritis with a site in France, this one is the 74th largest by planned enrollment of the 86 interventional ones that give a count, is one of 9 that started in 2026, is one of 48 with no phase, reaches primary completion later than 20 of the 37 other live ones, and was the 128th registered.

Osteoarthritis

2,978 studies on the registry are indexed under Osteoarthritis; 438 are open to participants now.

Browse Osteoarthritis studies →

Open to participants now

25 of the 136 studies in Osteoarthritis with a site in France are open now. Recruiting first, the newest first:

19 more — sign in →

All 25 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 285 Osteoarthritis studies recruiting now, 158 (55%) set no upper age limit and 70 (25%) stop at 75 or younger; 22 take children under 18; 31 take healthy volunteers.

This study: 75 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 136 studies in Osteoarthritis with a site in France, or all of them as a file.
02

Study summary

This single-centre, exploratory study at Montpellier University Hospital will investigate whether having low muscle mass and strength before hip-replacement surgery, a condition called sarcopenia, impact the return to everyday independence in people aged 75 years or older. About 20 volunteers, scheduled for surgery because of a recent femoral-neck fracture or severe arthritis that no longer responds to usual care, will give consent, answer brief health questionnaires, attempt simple walking and chair-rise tests if possible, and provide a small blood sample. While they are already under anaesthesia for their planned operation, the surgical team will take a tiny muscle sample through the same incision, so no extra cuts are needed. During the hospital stay or shortly after discharge, each participant will have a painless MRI scan of the thigh muscles and a very-low-dose bone scan (DXA) to measure muscle and bone health. The research team will then telephone participants at 3 and 6 months to ask about daily activities, walking ability, and any complications. The study lasts about six months for each person and does not alter their usual medical or rehabilitation care. Potential benefits include close follow-up, personalised feedback on muscle and bone results, and helping doctors learn whether pre-surgery muscle weakness predicts slower recovery-information that could guide future, more personalised exercise and nutrition programs. Extra study procedures carry only minimal risks: a routine blood draw, scans with none (MRI) or very little (DXA) radiation, and a muscle biopsy taken during surgery. Taking part is entirely voluntary, and participants may withdraw at any time without affecting their current or future care. The whole project will run for 18 months.

Read the detailed description

Hip-REGEN is an exploratory, single-centre, prospective, longitudinal pathophysiology study conducted at Montpellier University Hospital to clarify whether the degree of pre-operative sarcopenia modulates functional recovery after hip arthroplasty in patients ≥ 75 years who undergo the procedure either for a recent femoral-neck fracture or severe hip osteoarthritis.

The increasing worldwide burden of musculoskeletal diseases, represents major costs for the healthcare system. Osteoarthritis, which affects around 595 million people worldwide, and osteoporosis, defined by the WHO as a reduction in bone mineral density, are two of the main age-related musculoskeletal pathologies. In France, between 2008 and 2014, around 650,000 hip prostheses surgeries were necessary to treat severe coxofemoral osteoarthritis, and around 65,000 hip prostheses surgeries are necessary every year to treat fractures of the upper end of the femur, occuring mainly due to osteoporosis, associated with significant loss of autonomy and high one-year mortality rate (20%).

We hypothesise that lower muscle mass and strength before surgery will negatively impact the 3- and 6-month functional recovery, assessed by the Barthel Index. This association could be mediated by impaired muscle regenerative capacity and endocrine function, including myokines and related systemic circulating biomarkers. Twenty participants (10 hip fractures, 10 hip osteoarthritis) will be consecutively enrolled over 12 months, in the orthopaedic service, a sample size chosen to demonstrate feasibility and to cover the cost of ex-vivo assays while maintaining balanced sex representation. After written informed consent, baseline (Visit 1) assessments include Barthel Index, Katz ADL, Lawton IADL, physical activity (IPAQ-SF), SARC-F, comorbidity (Charlson), nutritional and cognitive screens, hand-grip dynamometry, and blood sampling for biobanking. Pre-operative sarcopenia status is classified according to EWGSOP2 thresholds for grip strength and appendicular lean mass by DXA (Visit 3), complemented by quantitative MRI (Visit 3) of the quadriceps to detect fatty infiltration that DXA may miss. All imageries will be performed either few days before or after the hip replacement for limited biais.

During the arthroplasty (Visit 2) a micro-biopsy of the gluteus medius is obtained through the surgical approach without additional incision, and bone-cartilage and synovium, normally discarded are collected and immediately transferred on ice to INSERM U1046 or U1183 for conditionning for cell culture, mechanistic assays and long-term storage (with participant opt-in for the biological collection). Within 15 days post-operatively (Visit 3) each participant undergoes a high-resolution quadriceps MRI and low-dose DXA to finalise muscle characterisation and obtain bone density. Telephone follow-ups at 3 months (Visit 4) and 6 months (Visit 5) repeat the Barthel Index and capture complications, readmissions and living arrangements; additional geriatric assessment is offered if recovery is unsatisfactory as part of routine care.

The primary endpoint is the variation in Barthel Index between baseline, 3 months, and 6 months. Key secondary analyses relate pre-operative sarcopenia metrics to: (i) in-vitro myoblast regeneration and endocrine function of skeletal muscle; (ii) circulating concentrations of muscle biomarkers (e.g. myostatin, follistatin, irisin, IL-6, IGF-1, lactate) ; and (iii) MRI-derived quadriceps composition. Laboratory procedures follow standardised culture and imaging protocols and include quality-controlled quantification of muscle satellite-cell (MuSC) proliferation, differentiation and senescence markers, as well as endocrine function including extracellular vesicle composition analysis, histological scoring of cartilage explants, and chondrocyte phenotypes and mesenchymal stem cells multipotency.

All data are entered into an electronic case-report form with automated range and consistency checks; monitoring is performed by the CHU Montpellier sponsor through on-site visits, central statistical surveillance and adherence to French Jardé Category-1 regulations (biopsy constitutes the main additional intervention). The statistical analysis plan, finalised before database lock, prespecifies descriptive statistics, non-parametric tests (Wilcoxon-Mann-Whitney, Fisher) for the primary endpoint, and exploratory Spearman correlations between sarcopenia measures, regenerative indices and functional change; given the pilot nature, 95 % confidence intervals will be reported without formal p-values.

Adverse events related to additional procedures are expected to be minimal (venepuncture, MRI without ionising radiation, DXA ≈0.001 mSv, and intra-operative muscle biopsy performed under the same anaesthesia). All events will be captured and reported according to Good Clinical Practice; a data-safety officer affiliated with the institutional vigilance unit will review safety quarterly. The study duration per participant is six months; the overall project, including analysis and dissemination, spans 18 months. Results, positive, negative or inconclusive, will be submitted to peer-reviewed journals and uploaded to ClinicalTrials.gov within one year of completion, in line with French and EU transparency requirements. By integrating in-vivo phenotyping, advanced imaging and ex-vivo regenerative testing across two complementary hip-surgery models, Hip-REGEN should generate mechanistic hypotheses and candidate biomarkers to guide future stratified rehabilitation or pre-habilitation trials in sarcopenic older adults.

03

Conditions studied

  • Sarcopenia in Elderly
  • Osteoarthritis (OA)
  • Hip Fracture Surgeries

Browse trials for

Keywords

  • Sarcopenia in Elderly
  • Osteoarthritis (OA)
  • Hip Fracture Surgeries
  • Functional Recovery
  • Rehabilitation
04

Who can participate

Ages eligible
75 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

- Elderly subjects undergoing surgical hip replacement for fracture of the upper end of the femur or severe hip osteoarthritis.

Exclusion Criteria for both groups :

  • to MRI : pacemaker, metallic implants.
  • Presence of a lower-limb prosthesis on the contralateral side to the surgery that may interfere with quadriceps mass measurements.
  • Progressive high-grade neoplasia.
  • Documented major cognitive disorders
  • Under legal protection measures (guardianship, conservatorship, or curatorship).
  • Subjects not affiliated with or not covered by a social security system.
  • Participation in another ongoing study with an active exclusion period.

Exclusion criteria - Fracture group :

  • Fracture with a suspicion of underlying neoplasia.
  • Placement of a lower-limb prosthesis on the surgical side within the last 12 months.
  • Inability to walk with or without human/technical assistance prior to fracture.

Exclusion criteria - Hip osteoarthritis group :

- Active inflammatory joint disease (rheumatoid arthritis, spondyloarthritis).

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Elderly subjects with a femoral neck fracture or severe hip osteoarthritis requiring surgery

    Procedure: Total hip replacement · Biological: Blood sampling · Biological: Muscle biopsies · Biological: Collection of joint samples derived from surgical waste · Radiation: DXA · Other: MRI · Other: Handgrip strength test

Interventions

  • ProcedureTotal hip replacement

    Hip replacement is a surgical procedure performed as part of routine care for patients with a fracture of the upper end of the femur or severe osteoarthritis of the hip.

  • BiologicalBlood sampling

    Four heparinized tubes of 5 ml of blood will be collected from each patient at inclusion. All blood samples will be stored in a biobank for subsequent analyses targeting biomarkers potentially associated with sarcopenia and muscle regeneration.

  • BiologicalMuscle biopsies

    Performed during hip arthroplasty

  • BiologicalCollection of joint samples derived from surgical waste

    Performed during hip arthroplasty

  • RadiationDXA

    Within 15 days following the surgical procedure, during hospitalization/rehabilitation

  • OtherMRI

    Within 15 days following the surgical procedure, during hospitalization/rehabilitation

  • OtherHandgrip strength test

    Measurement of handgrip strength using a hand dynamometer

06

What researchers measure

Primary outcomes

  1. Change from Baseline in the Barthel Index at 3 months post-operative

    A 10-point shift is the minimal clinically important difference; after hip-fracture surgery a mean 25-point decline at 3 months is anticipated.

    Time frame: Baseline and 3 months

  2. Change from Baseline in the Barthel Index at 6 months post-operative

    Time frame: Baseline and 6 months

  3. Measurement of hand-grip strength via dynamometry

    Assessment of preoperative sarcopenia severity

    Time frame: Baseline

  4. Measurement of appendicular lean mass by DXA

    Assessment of preoperative sarcopenia severity

    Time frame: Prior to surgery or within 7 days postoperatively

  5. Measurement of quadriceps mass by MRI

    Assessment of preoperative sarcopenia severity. Because DXA cannot differentiate intramuscular fat or connective tissue, 3-D Dixon/IDEAL MRI of the quadriceps-the muscle most affected by ageing-will segment contractile tissue and compute muscle mass (volume × 1.04 kg · L-¹).

    Time frame: Prior to surgery or within 7 days postoperatively

Secondary outcomes

  1. Number of myoblastic progenitors at proliferation onset

    Quantification, and correlation with Barthel-index at 3 month, of the number of myoblastic progenitor cells obtained after in-vitro proliferation for 3 days of primary human satellite cells isolated from \~25 mg gluteus micro-biopsies collected during surgery under general anaesthesia. The number of myoblasts will be determined by immunofluorescence staining and quantified using automated image analysis from at least five random microscopic fields per culture well (expressed as cells/mm² at day 3 of proliferation).

    Time frame: Intraoperative

  2. Mean myotube surface area at differentiation end

    Quantification, and correlation with Barthel-index at 3 month, of the mean surface area of myotubes at the end of the differentiation phase from primary human satellite cells isolated from \~25 mg gluteus-medius micro-biopsies collected during surgery under general anaesthesia. Myotube surface area will be determined by immunofluorescence staining and quantified using automated image analysis from at least five random microscopic fields per culture well, expressed in square micrometres (µm²).

    Time frame: Intraoperative

  3. Proportion of senescent MSCs

    Quantification, and correlation with Barthel-index at 3 month, of the proportion of senescent MSCs among primary MSC cultures isolated from bone fragments obtained during hip arthroplasty (surgical waste) by bone marrow flush. Senescence will be assessed using β-galactosidase staining, and the proportion of senescent cells will be calculated as the percentage of β-gal⁺ cells among total DAPI⁺ nuclei, averaged from at least five random microscopic fields per culture well (expressed as % of β-gal⁺ MSCs).

    Time frame: Intraoperative

  4. Number of chondrocytes obtained from MSCs at differentiation end

    Quantification, and correlation with Barthel-index at 3 month, of the number of chondrocytes obtained at the end of the differentiation phase from primary human mesenchymal stromal cells (MSCs) cultured in chondrogenic differentiation medium. Differentiated cells will be identified by immunofluorescence staining or histological coloration and quantified using automated image analysis from at least five random microscopic fields per culture well, expressed as number of cells per mm².

    Time frame: Intraoperative

  5. Number of adipocytes obtained from MSCs at differentiation end

    Quantification, and correlation with Barthel-index at 3 month, of the number of adipocytes obtained at the end of the differentiation phase from primary human mesenchymal stromal cells (MSCs) cultured in adipogenic differentiation medium. Differentiated cells will be identified by immunofluorescence staining or histological coloration and quantified using automated image analysis from at least five random microscopic fields per culture well, expressed as number of cells per mm².

    Time frame: Intraoperative

  6. Number of osteocytes obtained from MSCs at differentiation end.

    Quantification, and correlation with Barthel-index at 3 month, of the number of osteocytes obtained at the end of the differentiation phase from primary human mesenchymal stromal cells (MSCs) cultured in osteogenic differentiation medium. Differentiated cells will be identified by immunofluorescence staining or histological coloration and quantified using automated image analysis from at least five random microscopic fields per culture well, expressed as number of cells per mm².

    Time frame: Intraoperative

  7. Serum concentation of myostatin

    Preoperative circulating biomarkers predictive of post-arthrosplasty recovery will be identified and validated by quantifying candidate myokines in baseline serum via ELISA and multiplex assays and correlating with Barthel-index at 3 month.

    Time frame: Baseline and 3 month

  8. Serum concentation of myostatin

    Preoperative circulating biomarkers predictive of post-arthrosplasty recovery will be identified and validated by quantifying candidate myokines in baseline serum via ELISA and multiplex assays and correlating with Barthel-index at 6 month.

    Time frame: Baseline and 6 month

  9. Serum concentation of follistatin

    Preoperative circulating biomarkers predictive of post-arthrosplasty recovery will be identified and validated by quantifying candidate myokines in baseline serum via ELISA and multiplex assays and correlating with Barthel-index at 3 month.

    Time frame: Baseline and 3 month

  10. Serum concentation of follistatin

    Preoperative circulating biomarkers predictive of post-arthrosplasty recovery will be identified and validated by quantifying candidate myokines in baseline serum via ELISA and multiplex assays and correlating with Barthel-index at 6 month.

    Time frame: Baseline and 6 month

  11. Serum concentation of irisin

    Preoperative circulating biomarkers predictive of post-arthrosplasty recovery will be identified and validated by quantifying candidate myokines in baseline serum via ELISA and multiplex assays and correlating with Barthel-index at 3 month.

    Time frame: Baseline and 3 month

  12. Serum concentation of irisin

    Preoperative circulating biomarkers predictive of post-arthrosplasty recovery will be identified and validated by quantifying candidate myokines in baseline serum via ELISA and multiplex assays and correlating with Barthel-index at 6 month.

    Time frame: Baseline and 6 month

  13. Serum concentation of IL-6

    Preoperative circulating biomarkers predictive of post-arthrosplasty recovery will be identified and validated by quantifying candidate myokines in baseline serum via ELISA and multiplex assays and correlating with Barthel-index at 3 month.

    Time frame: Baseline and 3 month

  14. Serum concentation of IL-6

    Preoperative circulating biomarkers predictive of post-arthrosplasty recovery will be identified and validated by quantifying candidate myokines in baseline serum via ELISA and multiplex assays and correlating with Barthel-index at 6 month.

    Time frame: Baseline and 6 month

  15. Serum concentation of IGF-1

    Preoperative circulating biomarkers predictive of post-arthrosplasty recovery will be identified and validated by quantifying candidate myokines in baseline serum via ELISA and multiplex assays and correlating with Barthel-index at 3 month.

    Time frame: Baseline and 3 month

  16. Serum concentation of IGF-1

    Preoperative circulating biomarkers predictive of post-arthrosplasty recovery will be identified and validated by quantifying candidate myokines in baseline serum via ELISA and multiplex assays and correlating with Barthel-index at 6 month.

    Time frame: Baseline and 6 month

07

Study locations

1 of 1 sites recruiting
  • University Hospital
    Montpellier, 34090, France
    Recruiting
    • Jean Baptiste Robiaud, Assistant head physician · Contactjbrobiaud@gmail.com · +33629184092
    • Jean Baptiste ROBIAUD, Assistant head physician · Principal investigator
08

References and documents

Publications

  • GBD 2021 Osteoarthritis Collaborators. Global, regional, and national burden of osteoarthritis, 1990-2020 and projections to 2050: a systematic analysis for the Global Burden of Disease Study 2021. Lancet Rheumatol. 2023 Aug 21;5(9):e508-e522. doi: 10.1016/S2665-9913(23)00163-7. eCollection 2023 Sep. PubMed 37675071 ↗
  • Stein H, Perren SM, Cordey J, Kenwright J, Mosheiff R, Francis MJ. The muscle bed--a crucial factor for fracture healing: a physiological concept. Orthopedics. 2002 Dec;25(12):1379-83. doi: 10.3928/0147-7447-20021201-16. No abstract available. PubMed 12502201 ↗
  • Pedersen BK, Febbraio MA. Muscles, exercise and obesity: skeletal muscle as a secretory organ. Nat Rev Endocrinol. 2012 Apr 3;8(8):457-65. doi: 10.1038/nrendo.2012.49. PubMed 22473333 ↗
  • Brzeszczynska J, Meyer A, McGregor R, Schilb A, Degen S, Tadini V, Johns N, Langen R, Schols A, Glass DJ, Roubenoff R, Ross JA, Fearon KCH, Greig CA, Jacobi C. Alterations in the in vitro and in vivo regulation of muscle regeneration in healthy ageing and the influence of sarcopenia. J Cachexia Sarcopenia Muscle. 2018 Feb;9(1):93-105. doi: 10.1002/jcsm.12252. Epub 2017 Dec 6. PubMed 29214748 ↗
  • Fox KM, Magaziner J, Hawkes WG, Yu-Yahiro J, Hebel JR, Zimmerman SI, Holder L, Michael R. Loss of bone density and lean body mass after hip fracture. Osteoporos Int. 2000;11(1):31-5. doi: 10.1007/s001980050003. PubMed 10663356 ↗
  • Di Monaco M, Vallero F, Di Monaco R, Tappero R, Cavanna A. Muscle mass and functional recovery in men with hip fracture. Am J Phys Med Rehabil. 2007 Oct;86(10):818-25. doi: 10.1097/PHM.0b013e318151fec7. PubMed 17885314 ↗
  • Maden-Wilkinson TM, Degens H, Jones DA, McPhee JS. Comparison of MRI and DXA to measure muscle size and age-related atrophy in thigh muscles. J Musculoskelet Neuronal Interact. 2013 Sep;13(3):320-8. PubMed 23989253 ↗
  • Fuchs CJ, Kuipers R, Rombouts JA, Brouwers K, Schrauwen-Hinderling VB, Wildberger JE, Verdijk LB, van Loon LJC. Thigh muscles are more susceptible to age-related muscle loss when compared to lower leg and pelvic muscles. Exp Gerontol. 2023 May;175:112159. doi: 10.1016/j.exger.2023.112159. Epub 2023 Mar 31. PubMed 36967049 ↗
  • Vergara I, Vrotsou K, Orive M, Gonzalez N, Garcia S, Quintana JM. Factors related to functional prognosis in elderly patients after accidental hip fractures: a prospective cohort study. BMC Geriatr. 2014 Nov 26;14:124. doi: 10.1186/1471-2318-14-124. PubMed 25425462 ↗
  • Gielen E, Dupont J, Dejaeger M, Laurent MR. Sarcopenia, osteoporosis and frailty. Metabolism. 2023 Aug;145:155638. doi: 10.1016/j.metabol.2023.155638. Epub 2023 Jun 20. PubMed 37348597 ↗
  • Di Monaco M, Vallero F, Di Monaco R, Tappero R. Prevalence of sarcopenia and its association with osteoporosis in 313 older women following a hip fracture. Arch Gerontol Geriatr. 2011 Jan-Feb;52(1):71-4. doi: 10.1016/j.archger.2010.02.002. Epub 2010 Mar 5. PubMed 20207030 ↗
  • Haute Autorité de Santé. Prothèses de hanche. Saint-Denis La Plaine: HAS; 2013.
  • Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyere O, Cederholm T, Cooper C, Landi F, Rolland Y, Sayer AA, Schneider SM, Sieber CC, Topinkova E, Vandewoude M, Visser M, Zamboni M; Writing Group for the European Working Group on Sarcopenia in Older People 2 (EWGSOP2), and the Extended Group for EWGSOP2. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019 Jan 1;48(1):16-31. doi: 10.1093/ageing/afy169. PubMed 30312372 ↗
  • Clynes MA, Gregson CL, Bruyere O, Cooper C, Dennison EM. Osteosarcopenia: where osteoporosis and sarcopenia collide. Rheumatology (Oxford). 2021 Feb 1;60(2):529-537. doi: 10.1093/rheumatology/keaa755. PubMed 33276373 ↗
  • Candel-Parra E, Corcoles-Jimenez MP, Del Egido-Fernandez MA, Villada-Munera A, Jimenez-Sanchez MD, Moreno-Moreno M, Carrion-Gonzalez M, Denia-Cortes A. [Independence in activities of daily living 6 months after surgery in previously independent elderly patients with hip fracture caused by a fall]. Enferm Clin. 2008 Nov-Dec;18(6):309-16. doi: 10.1016/s1130-8621(08)75853-4. Spanish. PubMed 19080883 ↗
  • Maravic M, Taupin P, Landais P, Roux C. Change in hip fracture incidence over the last 6 years in France. Osteoporos Int. 2011 Mar;22(3):797-801. doi: 10.1007/s00198-010-1255-9. Epub 2010 Jun 2. PubMed 20517692 ↗
  • Desmond Curran, et al. Épidémiologie des fractures liées à l'ostéoporose en France : revue de la littérature, Revue du Rhumatisme, Volume 77, Issue 6, 2010, Pages 579-585,ISSN 1169-8330
  • Putman S, et al. Épidémiologie des prothèses de hanche en France : analyse de la base nationale du PMSI de 2008 à 2014, Revue de Chirurgie Orthopédique et Traumatologique,Volume 103, Issue 7, Supplement, 2017, Page S90, ISSN 1877-0517
  • Hunter DJ, Schofield D, Callander E. The individual and socioeconomic impact of osteoarthritis. Nat Rev Rheumatol. 2014 Jul;10(7):437-41. doi: 10.1038/nrrheum.2014.44. Epub 2014 Mar 25. PubMed 24662640 ↗
  • Kloppenburg M, Berenbaum F. Osteoarthritis year in review 2019: epidemiology and therapy. Osteoarthritis Cartilage. 2020 Mar;28(3):242-248. doi: 10.1016/j.joca.2020.01.002. Epub 2020 Jan 13. PubMed 31945457 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Feb 2028, 18 months after the start.

Of 578 non-industry interventional studies with no phase under Osteoarthritis, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 51. This study's planned 18 months is below that.

Counting every sponsor, half of 713 studies reached it within 28 months; a quarter within 11 and three quarters within 57.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 1, 2025
First posted
Feb 24, 2026
StartActual
Aug 17, 2026
Primary completionEst.
Feb 17, 2028
CompletionEst.
Aug 17, 2028
Last update
Sep 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07429955
Responsible party
Sponsor
First posted
Feb 24, 2026
Start date
Aug 17, 2026
Primary completion
Feb 17, 2028 (estimated)
Completion
Aug 17, 2028 (estimated)
Last update
Sep 10, 2026

Study contacts

Jean Baptiste ROBIAUD, Assistant head physician
Contact
jbrobiaud@gmail.com
+33629184092

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion